ANDA 62538, held by Strides Pharma Intl. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 62538 (Doxycycline Hyclate), held by Strides Pharma Intl, was first approved by FDA on Apr 7, 1986, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate and other antibacterial drugs, doxycycline hyclate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 1986 | Original application | Approved | None posted |
| Doxycycline HyclateEQ 100MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Doxycycline HyclateEQ 50MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Feb 6, 2026 | Supplement 22Labeling · Standard review | Approved | None posted |
| Feb 6, 2026 | Supplement 21Labeling · Standard review | Approved | None posted |
| Mar 31, 2025 | Supplement 19Labeling · Standard review | Approved | None posted |
| Mar 27, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Mar 27, 2025 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 27, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 16, 1993 | Supplement 9Manufacturing | Approved | None posted |
| Feb 23, 1991 | Supplement 8Manufacturing | Approved | None posted |
| May 8, 1989 | Supplement 7Manufacturing | Approved | None posted |
| Apr 7, 1986 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters